Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

- Anthim Dramatically Improves Survival in Animals with Clinical Symptoms of Anthrax disease -

PINE BROOK, N.J., April 20 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced the initiation of a second Phase I human safety trial of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO)

The Phase I dose-escalation trial is planned to enroll 45 healthy volunteers and is designed to expand the human safety database. Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented, "We are extremely pleased with the success of our development program for Anthim. Our drug consistently demonstrates remarkable efficacy in treating anthrax infection in animal models and is a strong candidate for addition to the Strategic National Stockpile."

The Company also reported the results of a previously conducted animal efficacy study. A single dose of Anthim provided a significant survival benefit (up to 94 percent survival in treated rabbits vs. 0 percent in controls) when administered to symptomatic rabbits. These results are consistent with several previous rabbit and primate studies that Elusys has conducted and show the dramatic protective effect of Anthim. Dr. Leslie Casey, Vice President of Research, commented, "Anthim has shown significant life-saving potential even when given in a single dose to symptomatic animals many hours after anthrax exposure. In earlier animal studies, Anthim provided 100 percent protection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Elusys, a private company based in Pine Brook, New Jersey, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit www.elusys.com.

    Contact:  Debra Duffy
              973 808 0222 x212
              dduffy@elusys.com


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Dental Implants ... ... for Dental Implants in US$ Million. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 through 2022. ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News ... ... publisher of cannabis market research, the legal cannabis market is ... through 2021, despite conflicting signals from the current presidential administration. ... that the two biggest drivers of growth in this industry ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 24, 2017 , ... “End Time GPS”: a dauntless and enlightened study ... Time GPS” is the creation of published author, Wesley Gerboth, a World War II ... and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon ...
(Date:3/24/2017)... ... , ... “The Communion of Saints: A Pastor’s Potpourri of ... across the United States. “The Communion of Saints” is the creation of ... congregations in seven states throughout his long career of devotion to the church. ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World ... that there could be four million Zika-related cases in the Americas within the next ... of US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
Breaking Medicine News(10 mins):